On Wednesday, Shares of Gap Inc (NYSE:GPS), added 1.09% and closed at $26.85 in the last trading session. The last trading range of the stock ranges between $26.34 and $26.93. The company’s Market capitalization is $10.76 Billion with the total Outstanding Shares of 398.48 million. During the 52-week trading session the minimum price at which share price traded, registered at $17.00 and reached to max level of $30.49. In celebration of International Day of the Girl, Gap Inc. recently declared the expansion of its signature education program, P.A.C.E. (Personal Advancement & Career Enhancement), with new curriculum designed to improve confidence and life skills for girls in community settings. To coincide with this declarement, the company’s namesake brand partnered with Condé Nast to showcase the inspirational stories of women who are presently participating in P.A.C.E.
At the center of Gap and Condé Nast’s partnership is a 12-minute documentary-style film profiling the stories of three unique women – Mary, Margaret and Puwaneshwary – who are presently enrolled in a P.A.C.E. community program. The film shines a light on how access to education has changed the lives of these women who work on a tea plantation in Sri Lanka, where literacy rates for women are typically very low – 67 percent contrast to the country’s average of 90 percent (source:CARE Sri Lanka).
Created by the award-winning 23 Stories x Condé Nast studio and directed by internationally acclaimed filmmaker Vanessa Black, the documentary premiers on Vogue’s digital channels in both the U.S. and the U.K. starting recently.
Provectus Biopharmaceuticals Inc (NYSEMKT:PVCT), dropped -3.94% and closed at $0.0682 in the last trading session. The last trading range of the stock ranges between $0.06 and $0.07. The company’s Market capitalization is $13.74 million with the total Outstanding Shares of 212.83 million. During the 52-week trading session the minimum price at which share price traded, registered at $0.06 and reached to max level of $0.56. Dr. Agarwala’s presentation reviewed the current studies underway for melanoma utilizing PV-10: the phase 3 clinical trial of intralesional PV-10 as a single agent therapy for locally advanced cutaneous melanoma (study PV-10-MM-31, clinicaltrials.gov identifier NCT02288897, EudraCT no. 2016-000317-78); and the phase 1b/2, study of intralesional PV-10 in combination with immune checkpoint inhibition (study PV-10-MM-1201, NCT02557321).
Study PV-10-MM-31 is an international multicenter, open-label, randomized controlled trial (RCT) of single-agent intralesional PV-10 as compared to systemic chemotherapy or intralesional oncolytic viral therapy to assess treatment of locally advanced cutaneous melanoma. A total of 225 patients with Stage IIIB to IV-M1a melanoma will be randomized in a 2:1 ratio against the comparator therapy for assessment of progression free survival.
Yandex NV (NASDAQ:YNDX), lost -5.79% and closed at $20.16 in the last trading session. The last trading range of the stock ranges between $20.08 and $21.36. During the 52-week trading session the minimum price at which share price traded, registered at $11.00 and reached to max level of $23.87. Recently Yandex (YNDX), a technology company that builds user-centric products and services powered by artificial intelligence, declares the launch of its global partnership program for Android handset manufacturers and telecom operators.
Yandex’s partners will preinstall its proprietary products, Yandex Browser and Yandex Launcher, to achieve device differentiation, enhance end user experience and gain additional income through its ad revenue sharing model. The first round of Yandex partners includes Fly, LAVA, Mobile TeleSystems, Multilaser, Posh Mobile, Wileyfox and ZTE, making Yandex products available in Europe, India, Latin America and Africa.
“Device manufacturers often have to choose between developing in-house software at a huge overhead cost or sacrificing product differentiation and additional revenue. Some OEMs pre-install as many apps as possible. Unfortunately, this has a negative effect on the user experience and is counterproductive to their brands in the long-term,” explained Artem Fokin, Vice President for International Business Development, Yandex. “Our software and artificial intelligence technology is aimed at shaking up the market and assisting our partners overcome these challenges, reduce customer churn and increase profit margins,” he continued.